In Brief: Hormel Buys CytoSport, FDA Warns On Drug Claims, Mira Health Consent Decree
This article was originally published in The Tan Sheet
Hormel flexes Muscle Milk for protein; Hangover prevention claims are disease claims; Mira Health cannot resume supplement production without FDA permission; Batch production records require details; Laclede needs drug approval for vaginal products and U.S. & Korea ink organic equivalency agreement.
You may also be interested in...
In Brief: CHPA Disagrees With FDA Warning; Adulterated Supplements Enforcement; DASCA Support Sought
FDA warns about painkillers for teething; enforcement against adulterated supplements; FDA warning letter for tainted bee pollen; Akorn must divest brands from Hi-Tech deal; senators seek support for DASCA; and consumer acetaminophen knowledge improves.
In Brief: NAD trims BPI claims, formula price-fixing in China, FDA warns Formulife and identifies spiked supplements, NBTY’s consumer redress
BPI discontinues claims at NAD’s behest; China levies fines for infant formula price-fixing; Public Citizen pans OTC Oxytrol; FDA advises ProNatural supplements cannot be topical; FDA warns Formulife on DMAA; FDA uncovers more spiked supplements; NBTY pays back consumers over omega-3 claims; Algean reminded about re-inspection fee.
A selection of articles you may have missed from August 2023, including a breakdown of CEO pay, a discussion on being out and proud in the life sciences sector, and some hopeful discourse on the investment landscape going into 2024.